7 Result(s) found
Current Studies
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRa-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The primary objective of the study is to evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (= 75%, = 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response. The primary endpoint is objective...
View DetailsCurrent Studies
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Particip
View DetailsCurrent Studies
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Primary Objectives: To evaluate the efficacy of INCB123667 monotherapy in participants with PROC with cyclin E1 overexpression (Cohort 1). Primary Endpoints: Objective response by IRC, defined as having a confirmed best overall response of CR or PR, as determined by IRC assessment per RECIST...
View DetailsCurrent Studies
Proximal FEmur Reconstruction or Internal Fixation fOR Metastases Randomized Controlled Trial PERFORM
The overall objective of the PERFORM trial is to determine the effect of resection and reconstruction on patient-important outcomes compared to internal fixation for the stabilization of an impending or realized pathologic fracture in patients with metastatic bone disease of the proximal femur. We...
View DetailsCurrent Studies
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Profici
To compare maintenance treatment with sacituzumab tirumotecan plus pembrolizumab to pembrolizumab alone with respect to PFS per RECIST 1.1 as assessed by BICR in participants with pMMR primary advanced or recurrent endometrial cancer To compare maintenance treatment with sacituzumab tirumotecan...
View DetailsCurrent Studies
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy
Primary Objective To determine investigator assessed progression-free survival using RECIST v1.1 (non-inferiority) for one vs. two years of maintenance olaparib. This analysis is supported by a modified ITT population limited to patients on protocol at least 360 days after randomization. The time...
View DetailsCurrent Studies